C4 Therapeutics, Inc. — Q2 2023 Form 10-Q
Business context and reporting period. This clinical-stage biopharmaceutical company reported results for the three and six months ended June 30, 2023. It is developing targeted protein degraders using its TORPEDO platform. It has no approved products and has not generated product-sales revenue; reported revenue comes from collaborations.
Financial results and liquidity
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Collaboration revenue | $2.7 million | $13.8 million | $6.4 million | $21.5 million |
| Research and development expense | $29.9 million | $31.3 million | $59.0 million | $57.5 million |
| General and administrative expense | $10.3 million | $9.9 million | $21.3 million | $22.7 million |
| Operating loss | $37.6 million | $27.4 million | $73.8 million | $58.8 million |
| Net loss | $35.9 million | $27.4 million | $70.7 million | $59.0 million |
| Net loss per share | $0.73 | $0.56 | $1.44 | $1.21 |
| Operating cash used | Not separately presented | Not separately presented | $52.1 million | $48.8 million |
At June 30, cash and cash equivalents were $44.9 million, marketable securities were $241.8 million, and cash, cash equivalents and marketable securities totaled approximately $286.7 million. The company had $233.7 million of stockholders’ equity and $141.3 million of total liabilities. It reported $10.3 million of related-party debt, all classified as current at quarter-end. Interest expense on the debt was $1.2 million for the first half. The company repaid the remaining loan principal on July 26, 2023, after the lender waived the prepayment fee.
Operating cash burn increased year over year in the first half. Investing cash flow was positive $68.7 million, primarily reflecting net maturities of marketable securities; financing cash flow was negative $1.4 million, including $1.5 million of debt principal payments. No conventional product gross margin is reported; collaboration revenue is the company’s only current revenue source.
Material changes versus the prior comparable period
- Q2 collaboration revenue fell $11.2 million year over year; first-half revenue fell $15.1 million. The decline reflects lower revenue from Biogen and Roche and completion of Calico’s performance obligation. Biogen’s research term ended in June 2023, though certain nominated-target activities continue for a period afterward; Calico’s research term ended in March 2023.
- First-half net loss widened by $11.7 million. Higher clinical-trial spending and lower collaboration revenue more than offset reduced preclinical costs and general and administrative expense.
- First-half R&D spending rose $1.4 million as clinical expenses increased $4.0 million, partly offset by lower IND-enabling and preclinical costs. Interest and other income increased to $4.3 million from $0.8 million, reflecting higher investment yields.
- Marketable securities declined to $241.8 million from $307.4 million at December 31, 2022, while cash and cash equivalents increased to $44.9 million from $29.8 million.
Outlook, developments and risks
- Management’s financial statements state that available cash, cash equivalents and marketable securities are expected to fund operations for at least 12 months from issuance. Separately, the risk discussion estimates funding into the second half of 2025, based partly on the expected Betta share purchase and future collaboration receipts, excluding certain milestones. The longer estimate depends on assumptions that may prove incorrect; management says additional capital will be needed to fund candidates through regulatory approval.
- Betta Pharma paid a $10 million upfront amount for Greater China rights to CFT8919; no revenue from the agreement was recognized by June 30, with recognition expected to begin upon delivery of clinical supply. Betta Investment had also agreed to buy 5,567,928 shares for approximately $25 million ($4.49 per share), but the stock purchase had not closed at quarter-end and remained subject to conditions.
- The company reported ongoing Phase 1/2 trials of CFT7455, CFT8634 and CFT1946. The FDA cleared the CFT8919 IND in June; C4 Therapeutics expects to begin clinical activities outside Greater China after Betta’s Phase 1 dose-escalation trial there. CFT7455’s dosing schedule had previously been modified in response to observed safety signals.
- Key risks include clinical efficacy, safety and enrollment uncertainty; the unproven targeted-protein-degradation approach; reliance on third-party manufacturers and CROs; collaboration-partner execution and termination risk; intellectual-property disputes; competition; and the need for additional financing. The company had filed a petition challenging a third-party BRD9-related patent and disclosed that the outcome is uncertain.
- No material legal proceedings were reported. Management concluded disclosure controls were effective as of June 30, 2023, and reported no material change in internal control over financial reporting during the quarter. No formal financial guidance was provided.
Important facts for investors to verify
- Whether the Betta Investment share purchase closed, and the timing and use of any proceeds; the filing states it was unclosed at June 30.
- Actual cash burn, collaboration receipts and updated runway assumptions, particularly the conditions underlying the second-half 2025 estimate.
- Progress, enrollment, safety findings and data updates for the three active clinical programs, including the CFT7455 dosing changes.
- The effect of the completed Biogen and Calico research terms on future collaboration revenue, and progress under Roche and Betta agreements.
- Confirmation of the July 26 debt repayment and release of liens, and whether additional financing or dilution will be required.